Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
fampridine
internuclear ophthalmoplegia
multiple sclerosis
video-oculography
Journal
CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
17
10
2018
accepted:
08
12
2018
pubmed:
14
2
2019
medline:
10
10
2020
entrez:
14
2
2019
Statut:
ppublish
Résumé
To examine whether the velocity of saccadic eye movements in internuclear ophthalmoparesis (INO) improves with fampridine treatment in patients with multiple sclerosis (MS). Randomized, double-blind, placebo-controlled, cross-over trial with fampridine in patients with MS and INO. Horizontal saccades were recorded at baseline and at multiple time points post-dose. Main outcome measures were the change of peak velocity versional dysconjugacy index (PV-VDI) and first-pass amplitude VDI (FPA-VDI). Both parameters were compared between fampridine and placebo using a mixed model analysis of variance taking patients as their own control. Pharmacokinetics was determined by serial blood sampling. Thirteen patients had a bilateral and 10 had a unilateral INO. One patient had an INO of abduction (posterior INO of Lutz) and was excluded. Fampridine significantly reduced both PV-VDI (-17.4%, 95% CI: -22.4%, -12.1%; P < 0.0001) and FPA-VDI (-12.5%, 95% CI: -18.9%, -5.5%; P < 0.01). Pharmacokinetics demonstrated that testing coincided with the average t Fampridine improves saccadic eye movements due to INO in MS. Treatment response to fampridine may gauge patient selection for inclusion to remyelination strategies in MS using saccadic eye movements as primary outcome measure.
Identifiants
pubmed: 30756475
doi: 10.1111/cns.13096
pmc: PMC6515699
doi:
Substances chimiques
Potassium Channel Blockers
0
4-Aminopyridine
BH3B64OKL9
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-703Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2019 The Authors CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
Références
Nat Rev Neurol. 2014 Aug;10(8):447-58
pubmed: 25002105
Muscle Nerve. 1980 Mar-Apr;3(2):112-9
pubmed: 6245355
Science. 1985 Jun 28;228(4707):1502-7
pubmed: 2409596
J Neurol. 2017 Mar;264(3):600-602
pubmed: 28194531
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
J Neurol Neurosurg Psychiatry. 2002 Jul;73(1):51-5
pubmed: 12082045
Nat Rev Neurol. 2015 Nov;11(11):637-45
pubmed: 26369516
J Neurol. 2008 Jul;255(7):1006-11
pubmed: 18446308
Ann N Y Acad Sci. 2002 Apr;956:438-40
pubmed: 11960834
Arch Neurol. 1986 May;43(5):438-43
pubmed: 3964108
PLoS One. 2018 Jul 16;13(7):e0200695
pubmed: 30011322
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
Brain. 2017 Nov 1;140(11):2776-2796
pubmed: 29053779
J Neurol Sci. 2003 Jun 15;210(1-2):65-71
pubmed: 12736091
Mult Scler. 2003 Feb;9(1):55-8
pubmed: 12617269
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Curr Med Res Opin. 2013 Dec;29(12):1637-45
pubmed: 23157466
J Neurol Sci. 1991 Apr;102(2):144-9
pubmed: 2072115
Arch Neurol. 1985 Sep;42(9):851-5
pubmed: 4026628
Neurology. 2014 Jul 8;83(2):192-4
pubmed: 24907233
JAMA Neurol. 2018 Oct 1;75(10):1246-1255
pubmed: 29971335
Ann N Y Acad Sci. 2011 Sep;1233:313-9
pubmed: 21951010
Lancet. 2009 Feb 28;373(9665):732-8
pubmed: 19249634
Lancet. 1999 Mar 20;353(9157):964-9
pubmed: 10459905
J Neurol. 2003 May;250(5):569-75
pubmed: 12736736
Neurology. 2008 Mar 25;70(13 Pt 2):1098-106
pubmed: 18287569
CNS Neurosci Ther. 2019 Jun;25(6):697-703
pubmed: 30756475
N Engl J Med. 1982 Jun 24;306(25):1529-33
pubmed: 7043271
Pract Neurol. 2017 Apr;17(2):149-153
pubmed: 27927777
Pharm Res. 2018 Jun 18;35(8):159
pubmed: 29915999
Neurology. 2001 Sep 11;57(5):762-8
pubmed: 11552000
Lancet Neurol. 2017 Mar;16(3):189-199
pubmed: 28229892